Literature DB >> 35189133

Pathology of hyperandrogenemia in the oocyte of polycystic ovary syndrome.

Neil R Chappell1, William E Gibbons1, Chellakkan S Blesson2.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common ovulatory disorder in the world and is associated with multiple adverse outcomes. The phenotype is widely varied, with several pathologies contributing to the spectrum of the disease including insulin resistance, obesity and hyperandrogenemia. Of these, the role of hyperandrogenemia and the mechanism by which it causes dysfunction remains poorly understood. Early studies have shown that androgens may affect the metabolic pathways of a cell, and this may pose hazards at the level of the mitochondria. As mitochondria are strictly maternally inherited, this would provide an exciting explanation not only to the pathophysiology of PCOS as a disease, but also to the inheritance pattern. This review seeks to summarize what is known about PCOS and associated adverse outcomes with focus on the role of hyperandrogenemia and specific emphasis on the oocyte.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Embryo; Hyperandrogenemia; Oocyte; PCOS; Polycystic ovary syndrome

Mesh:

Substances:

Year:  2022        PMID: 35189133      PMCID: PMC8920773          DOI: 10.1016/j.steroids.2022.108989

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  114 in total

1.  Obesity and reproduction: a committee opinion.

Authors: 
Journal:  Fertil Steril       Date:  2015-10-01       Impact factor: 7.329

2.  A comparison of the miscarriage rate between women with and without polycystic ovarian syndrome undergoing IVF treatment.

Authors:  Liu Liu; Xiaomei Tong; Lingying Jiang; T C Li; Feng Zhou; Songying Zhang
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2014-03-12       Impact factor: 2.435

Review 3.  Actions of 17β-estradiol and testosterone in the mitochondria and their implications in aging.

Authors:  Andrea Vasconsuelo; Lorena Milanesi; Ricardo Boland
Journal:  Ageing Res Rev       Date:  2013-09-14       Impact factor: 10.895

4.  Maternal Metabolic Syndrome Programs Mitochondrial Dysfunction via Germline Changes across Three Generations.

Authors:  Jessica L Saben; Anna L Boudoures; Zeenat Asghar; Alysha Thompson; Andrea Drury; Wendy Zhang; Maggie Chi; Andrew Cusumano; Suzanne Scheaffer; Kelle H Moley
Journal:  Cell Rep       Date:  2016-06-16       Impact factor: 9.423

5.  Molecular abnormalities in oocytes from women with polycystic ovary syndrome revealed by microarray analysis.

Authors:  Jennifer R Wood; Daniel A Dumesic; David H Abbott; Jerome F Strauss
Journal:  J Clin Endocrinol Metab       Date:  2006-12-05       Impact factor: 5.958

Review 6.  Obesity and female infertility: potential mediators of obesity's impact.

Authors:  Darcy E Broughton; Kelle H Moley
Journal:  Fertil Steril       Date:  2017-03-11       Impact factor: 7.329

Review 7.  Mitochondrial function in the human oocyte and embryo and their role in developmental competence.

Authors:  Jonathan Van Blerkom
Journal:  Mitochondrion       Date:  2010-10-07       Impact factor: 4.160

Review 8.  Obesity induces ovarian inflammation and reduces oocyte quality.

Authors:  Alexandria P Snider; Jennifer R Wood
Journal:  Reproduction       Date:  2019-09       Impact factor: 3.906

9.  Association between Body Mass Index and Reproductive Outcome in Women with Polycystic Ovary Syndrome Receiving IVF/ICSI-ET.

Authors:  Han Zhou; Dan Zhang; Zhuoye Luo; Aimin Yang; Na Cui; Guimin Hao; Wei Wang
Journal:  Biomed Res Int       Date:  2020-08-21       Impact factor: 3.411

10.  Rethinking Human Embryo Research Policies.

Authors:  Kirstin R W Matthews; Ana S Iltis; Nuria Gallego Marquez; Daniel S Wagner; Jason Scott Robert; Inmaculada de Melo-Martín; Marieke Bigg; Sarah Franklin; Soren Holm; Ingrid Metzler; Matteo A Molè; Jochen Taupitz; Giuseppe Testa; Jeremy Sugarman
Journal:  Hastings Cent Rep       Date:  2021-01       Impact factor: 2.683

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.